[1]
|
Smith, P.K., Goodnough, L.T., Levy, J.H., Poston, R.S., Short, M.A., Weerakkody, G.J. and Lenarz, L.A. (2012) Mortality Benefit with Prasugrel in the TRITON-TIMI 38 Coronary Artery Bypass Grafting Cohort: Risk-Adjusted Retrospective Data Analysis. Journal of the American College of Cardiology, 60, 388-396.
https://doi.org/10.1016/j.jacc.2012.03.030
|
[2]
|
Hansson, E.C., Jideus, L., Aberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., Ivert, T., Nozohoor, S., Barbu, M., Svedjeholm, R. and Jeppsson, A. (2016) Coronary Artery Bypass Grafting-Related Bleeding Complications in Patients Treated with Ticagrelor or Clopidogrel: A Nationwide Study. European Heart Journal, 37, 189-197.
https://doi.org/10.1093/eurheartj/ehv381
|
[3]
|
Tomsic, A., Schotborgh, M.A., Manshanden, J.S.J., Li, W.W.L. and de Mol, B.A.J.M. (2016) Coronary Artery Bypass Grafting-Related Bleeding Complications in Patients Treated with Dual Antiplatelet Treatment. European Journal of Cardio-Thoracic Surgery, 50, 849-856. https://doi.org/10.1093/ejcts/ezw149
|
[4]
|
Pickard, A.S., Becker, R.C., Schumock, G.T. and Frye, C.B. (2008) Clopidogrel-Ass- ociated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting. Pharmacotherapy, 28, 376-392.
https://doi.org/10.1592/phco.28.3.376
|
[5]
|
Purkayastha, S., Athanasiou, T., Malinovski, V., Tekkis, P., Foale, R., Casula, R., Glenville, B. and Darzi, A. (2006) Does Clopidogrel Affect Outcome after Coronary Artery Bypass Grafting? A Meta-Analysis. Heart, 92, 531-532.
https://doi.org/10.1136/hrt.2004.058396
|
[6]
|
Windecker, S., Kolh, P., Alfonso, F., Collet, J.P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S.J., Juni, P., Kappetein, A.P., Kastrati, A., Knuuti, J., Landmesser, U., Laufer, G., Neumann, F.J., Richter, D.J., Schauerte, P., Sousa Uva, M., Stefanini, G.G., Taggart, D.P., Torracca, L., Valgimigli, M., Wijns, W. and Witkowski, A. (2014) 2014 ESC/EACTS Guidelines on Myocardial Revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the Special Contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 35, 2541-2619.
https://doi.org/10.1093/eurheartj/ehu278
|
[7]
|
Ferraris, V.A., Saha, S.P., Oestreich, J.H., Song, H.K., Rosengart, T., Reece, T.B., Mazer, C.D., Bridges, C.R., Despotis, G.J., Jointer, K. and Clough, E.R. (2012) Society of Thoracic Surgeons. 2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. The Annals of Thoracic Surgery, 94, 1761-1781.
https://doi.org/10.1016/j.athoracsur.2012.07.086
|
[8]
|
Wallentin, L. (2009) P2Y12 Inhibitors: Differences in Properties and Mechanisms of Action and Potential Consequences for Clinical Use. European Heart Journal, 30, 1964-1977. https://doi.org/10.1093/eurheartj/ehp296
|
[9]
|
Gurbel, P.A., Bliden, K.P., Butler, K., Tantry, U.S., Gesheff, T., Wei, C., Teng, R., Antonino, M.J., Patil, S.B., Karunakaran, A., Kereiakes, D.J., Parris, C., Purdy, D., Wilson, V., Ledley, G.S. and Storey, R.F. (2009) Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients with Stable Coronary Artery Disease: The ONSET/OFFSET Study. Circulation, 120, 2577-2585.
https://doi.org/10.1161/CIRCULATIONAHA.109.912550
|
[10]
|
Angiolillo, D.J., Firstenberg, M.S., Price, M.J., Tummala, P.E., Hutyra, M., Welsby, I.J., et al. (2012) Bridging Antiplatelet Therapy with Cangrelor in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial. JAMA, 307, 265-274.
https://doi.org/10.1001/jama.2011.2002
|
[11]
|
Qamar, A. and Bhatt, D.L. (2016) Current Status of Data on Cangrelor. Pharmacology & Therapeutics, 159, 102-109. https://doi.org/10.1016/j.pharmthera.2016.01.004
|